...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: The crick didn’t rise, here’s the presentation, finally!

Thanks for the additional detail. 
Exciting times ahead.

Share
New Message
Please login to post a reply